) has been revised to $4.23 / share. This is an increase of 22.06% from the prior estimate of $3.47 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...

Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have begun coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a Buy rating and a ...

Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the hot stocks to buy with huge upside potential. On October 10, B. Riley raised the firm’s price target on Ovid Therapeutics to $5 from $3 and kept a ...

Fintel reports that on December 22, 2025, LifeSci Capital initiated coverage of Ovid Therapeutics (NasdaqCM:OVID) with a Outperform recommendation. As of December 21, 2025, the average one-year price ...

Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for ...

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need ...

Romulus, N.Y. — On a frigid January night, a ferocious blaze destroyed an entire block of a tiny Finger Lakes village. The Jan. 21 fire in Ovid took down four buildings full of apartments and ...

The average one-year price target for Ovid Therapeutics (NasdaqCM:OVID) has been revised to $4.23 / share. This is an increase of 22.06% from the prior estimate of $3.47 dated September 27, 2025. The ...